New study to see if heart procedure beats standard care for AF and heart failure

NCT ID NCT07254455

Not yet recruiting Disease control Sponsor: Tulane University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a heart procedure called catheter ablation to standard medical treatment for people with atrial fibrillation (an irregular heartbeat) and heart failure with preserved ejection fraction (a type of heart failure where the heart pumps normally but is stiff). The goal is to see if ablation reduces the risk of death, stroke, or hospitalization. About 900 participants will be randomly assigned to one of the two treatments and followed for three years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: catheter ablation
What this could lead to: If successful, this could provide a better treatment option for people with both atrial fibrillation and heart failure, potentially reducing deaths, strokes, and hospital stays.
What could go wrong: This is a large trial but has not started recruiting yet. Catheter ablation is an invasive procedure with risks like bleeding, infection, or heart rhythm problems. The benefit over standard care is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation diastolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION HEART FAILURE WITH PRESERVED EJECTION FRACTION

More trials for these conditions

Other studies related to the condition(s) this trial covers.